Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Participating in a fecal occult blood test (FOBT) screening program was linked to a 43% reduction in colorectal cancer (CRC) mortality, according to a large Swedish prospective study. Even just receiving an invitation to screen was tied to a 26% drop in CRC deaths. The catch? The benefit only materializes when patients follow through — making outreach and adherence critical.
A major Swedish prospective study involving over 375,000 adults aged 60–69 found that participation in a fecal occult blood test (FOBT) screening program was associated with a 43% reduction in colorectal cancer (CRC) mortality — far greater than previously estimated. Even simply being invited to screen was tied to a 26% drop in CRC deaths. The study, published in JAMA Network Open, refined earlier estimates by adjusting for "contamination bias" — a common problem where control group members also end up getting screened, muddying the results.
Supporting evidence comes from Spain's Basque Country, where a 21-year population study found that a biennial FIT-based screening program cut CRC mortality by ~50% among adults aged 50–69, with the decline becoming apparent just 3 years after the program launched. About 70.8% of screen-detected cancers were caught at stage I or II.
By the Numbers
Why it matters: The data make a compelling case that organized, population-level CRC screening programs save lives — but the benefit hinges on patient participation. Clinicians encouraging eligible patients to complete stool-based tests and follow up on positive results may be making one of the highest-impact moves available in routine care.
